ClinicalTrials.gg
Not yet recruitingNCT07446010HEMOCT INDIAUpdated Oct 21, 2026

Post Approval Phase 4 Study to Learn More About How Safe Octocog Alfa is, and How Well it Works in Patients With Severe Hemophilia A in India

An observational study in Severe Hemophilia A, sponsored by Bayer. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Bayer · Observational

Updated Oct 21, 2026No longer in IndiaStart date moved+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies in Hemophilia A by Bayer — 3 open to participants now, 6 under way, none of them phase 3. Hemophilia A · Bayer.

Planned enrollment
20th of 26
30 · median 67
Started
2027
the only one that year
Observational
26 of 57
3 open now
Registered
57th of 57
by date

Among the 57 studies in Hemophilia A by Bayer, this one is the 20th largest by planned enrollment of the 26 observational ones that give a count, is the only one that started in 2027, is one of 26 observational ones, and was the 57th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

3 of the 57 studies in Hemophilia A by Bayer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Hemophilia A by Bayer, or all of them as a file.
02

Study summary

Hemophilia A is a genetic condition that makes it hard for blood to clot properly. This happens because the body does not have enough of a protein called Factor VIII, which helps stop bleeding. The main goal of treating someone with hemophilia is to stop and prevent bleeding by giving them the missing Factor VIII. This treatment can be given when a person starts bleeding (called on-demand treatment), or it can be given regularly to prevent bleeding (called prophylactic therapy). In India, most people with hemophilia A get treatment only when they have a bleeding episode, and only a few receive regular preventive treatment. Octocog alfa (also known as BAY 81-8973) is a modern, laboratory-made version of Factor VIII. It is made without using any human or animal materials and has special features that help it work better in the body. In India, Octocog alfa is approved for use in adults and children with hemophilia A to: - Treat and control bleeding episodes when they happen - Manage bleeding during surgery - Prevent bleeding by giving regular treatment The safety and effectiveness of Octocog alfa have been shown in several global studies. This new study is required by Indian health authorities to collect information about how safe Octocog alfa is and how well it works in people with hemophilia A who have already received treatment. The study will look at how Octocog alfa is used in real-life medical practice in India, including how doctors prescribe it, how patients use it, and what treatment results they have.

03

Conditions studied

  • Severe Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Male adult patients (aged ≥18 years) with severe Hemophilia A in India, who have been previously treated for at least 100 exposure days to FVIII concentrate(s) and are prescribed Octocog alfa for managing bleeding episodes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients aged 18 years or older with a documented diagnosis of severe Hemophilia A, defined by a baseline Factor VIII (FVIII) activity level of less than 1% (\<0.01 IU/mL) in accordance with the Hemophilia Severity Classification
  • Previously treated with FVIII concentrate(s) (plasma derived or recombinant, including Octocog alfa) either on-demand or prophylactically for at least 100 Exposure Days (EDs).
  • Patients for whom the decision to initiate on-demand treatment with Octocog alfa for acute bleeding was made as per the investigator's routine treatment practice. This will include patients who are already on on-demand treatment with Octocog alfa as well.
  • Written from the patient or legal representative

Exclusion criteria

Exclusion Criteria:

  • Known according to the local prescriber information
  • Patients who are participating in an program with interventions outside of routine clinical practice.
  • Patients with any other diagnosis of bleeding/coagulation disorder other than Hemophilia A.
  • Patients who are on ongoing prophylactic treatment with any FVIII concentrate or non-factor treatments like emicizumab.
  • Patients exhibiting any of the following laboratory abnormalities at screening:
  • Known count \<100,000 mm3
  • Known Serum Creatinine >2 folds upper the normal limit
  • Known Hepatic or ALT >5 folds upper the normal limit
  • Patients who have received an on-demand infusion with any other FVIII (different to Octocog alfa), FVII or Activated prothrombin complex concentrate product (aPCC/FEIBA) 72 hours before the enrollment.
  • History or presence of FVIII inhibitor with a titer ≥ 0.6 with Nijmegen modified Bethesda Assay (NBA), or a clinical history suggestive of an inhibitor necessitating changes to treatment
  • Patient concerns or other barriers precluding adequate understanding or cooperation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Male adult patients (aged ≥18 years) with severe Hemophilia A in India, who have been previously tre

    Drug: Octocog alfa

Interventions

  • unmodified, full-length recombinant human FVIII (rFVIII) dosing according to local label and treating physician

    Also known as: BAY 81-8973, Kovaltry, Antihaemorrhagic agent, blood coagulation factor VIII

06

What researchers measure

Primary outcomes

  1. Duration of treatment emergent adverse event (TEAEs) and serious adverse events (TESAEs)

    Time frame: 12 weeks

  2. Severity of treatment emergent adverse event (TEAEs) and serious adverse events (TESAEs)

    Time frame: 12 weeks

  3. Treatment administered for treatment emergent adverse event (TEAEs) and serious adverse events (TESAEs)

    Time frame: 12 weeks

  4. Laboratory test results related to adverse events of special interest (AESIs)rse events (TESAEs)

    Time frame: 12 weeks

Secondary outcomes

  1. Total number of infusions per bleed

    Time frame: 12 weeks

  2. Dose of Octocog alfa (IU/kg) per bleed

    Time frame: 12 weeks

  3. Location of bleeds

    Time frame: 12 weeks

  4. Type of bleeds

    Time frame: 12 weeks

  5. Severity of bleeds

    Time frame: 12 weeks

  6. Duration of bleeds

    Time frame: 12 weeks

  7. Investigator rating of response

    poor, moderate, good, excellent

    Time frame: 12 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2027; primary completion for Mar 2028, 11 months later.

Of 53 industry-sponsored observational studies under Hemophilia A, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 79. This study's planned 11 months is below that.

Counting every sponsor, half of 131 studies reached it within 45 months; a quarter within 25 and three quarters within 79.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Sep 2026 → Apr 2027, primary completion Sep 2027 → Mar 2028 and completion Sep 2027 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Mar 3, 2026
StartEst.
Apr 5, 2027was Sep 2026
Primary completionEst.
Mar 31, 2028was Sep 2027
CompletionEst.
Mar 31, 2028was Sep 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites removed; no longer in India
Show 6 removed
  • Department of Medicine Assam Medical College & Hospital · Dibrugarh, India
  • Government of Medical College Kozhikode · Kozhikode, India
  • Sanjay Gandhi Post Graduate Institute & Medical Sciences · Lucknow, India
  • Christian Medical College & Hospital · Ludhiana, India
  • All India Institute Of Medical Sciences · New Delhi, India
  • Sahyadri Super Speciality Hospital · Pune, India
Oct 21, 2026
Start date
Sep 1, 2026→Apr 5, 2027
Oct 21, 2026
Primary completion
Sep 30, 2027→Mar 31, 2028
Oct 21, 2026
Study completion
Sep 30, 2027→Mar 31, 2028
Oct 21, 2026
Enrollment
33→30
Oct 21, 2026
Eligibility
Sex MALE→ALL
Oct 21, 2026
Interventions
Arm changed Group 1→Male adult patients (aged ≥18 years) with severe Hemophilia A in India, who have been previously tre
Oct 21, 2026
Primary outcomes
1 removed, 2 description edited
What changed in the outcomes
  • RemovedOutcome of treatment emergent adverse event (TEAEs) and serious adverse events (TESAEs)Time frame: 12 weeks
  • DescriptionLaboratory test results related to adverse events of special interest (AESIs)rse events (TESAEs): how it is measured was reworded
  • DescriptionSeverity of treatment emergent adverse event (TEAEs) and serious adverse events (TESAEs): how it is measured was reworded
Oct 21, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionSeverity of bleeds: how it is measured was reworded
Oct 21, 2026
Title
Post Approval ObservationalPhase 4 Study to Learn More About How Safe Octocog Alfa is, and How Well it Works in Patients With Severe Hemophilia A in India
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    6 sites removed; no longer in India
    Show 6 removed
    • Department of Medicine Assam Medical College & Hospital · Dibrugarh, India
    • Government of Medical College Kozhikode · Kozhikode, India
    • Sanjay Gandhi Post Graduate Institute & Medical Sciences · Lucknow, India
    • Christian Medical College & Hospital · Ludhiana, India
    • All India Institute Of Medical Sciences · New Delhi, India
    • Sahyadri Super Speciality Hospital · Pune, India
    Start date Sep 1, 2026→Apr 5, 2027
    Primary completion Sep 30, 2027→Mar 31, 2028
    Study completion Sep 30, 2027→Mar 31, 2028
    Enrollment 33→30
    Eligibility Sex MALE→ALL
    Primary outcomes 1 removed, 2 description edited
    What changed in the outcomes
    • RemovedOutcome of treatment emergent adverse event (TEAEs) and serious adverse events (TESAEs)Time frame: 12 weeks
    • DescriptionLaboratory test results related to adverse events of special interest (AESIs)rse events (TESAEs): how it is measured was reworded
    • DescriptionSeverity of treatment emergent adverse event (TEAEs) and serious adverse events (TESAEs): how it is measured was reworded
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionSeverity of bleeds: how it is measured was reworded
    Interventions Arm changed Group 1→Male adult patients (aged ≥18 years) with severe Hemophilia A in India, who have been previously tre
    Title Post Approval ObservationalPhase 4 Study to Learn More About How Safe Octocog Alfa is, and How Well it Works in Patients With Severe Hemophilia A in India
    + 7 other changes: index terms, verification date, responsible party, oversight details, description, conditions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07446010
Lead sponsor
Bayer
Collaborators
Clinical Research Organization - JSS Medical Research
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Apr 5, 2027 (estimated)
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Bayer Clinical Trials Contact
Contact
clinical-trials-contact@bayer.com
18888422937
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion